Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Journal of Translational Medicine

Figure 1

From: Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer

Figure 1

Screening of immunogenic epitopes of HPV18 E7 which could sensitize PBMCs of four major HLA class I using IFN-γ ELISpot assay. ELISpot assays were performed to measure IFN-γ production from donor’s PBMCs of four major HLA class I that were sensitized with 24 candidate peptides. HPV18 E781–95 (#21) and E789–103 (#23) induced greater number of IFN-γ+ spots from PBMCs of HLA-A*02:01 (A), HLA-A*24:02 (B), HLA-A*11:01 (C), HLA-A*33:03 (D) than other peptides. Data are representative of at least three independent experiments using PBMCs from HLA-A*02:01, HLA-A*24:02, HLA-A*11:01, HLA-A*33:03 subjects. PBMCs sensitized with PHA were used as a positive control (PHA), and PBMCs with sensitized with no peptide (No peptide) were used as the negative control (N.C). Data are presented as mean ± standard error. Statistically significant differences between the tested group and negative control group were determined using a student t-test (two-tailed). **P < .001; *P < .05.

Back to article page